Observational studyBMC pediatrics2024
Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre.
Observational study in BMC pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 7 citations in OpenAlex.
- Endocrinopathies and growth in a UK cohort of children with transfusion dependent thalassaemia.British journal of haematology · 2026Observational
- Integrative analysis of single nucleotide polymorphism of PDE7B (rs2327669) with biopsychosocial and biochemical parameters in β-thalassemia major patients in Pakistani Cohort.Molecular biology reports · 2026Article
- Cord Blood-Based Neonatal Screening for Hemoglobinopathies in Northern Tunisia.International journal of neonatal screening · 2025Article
- Clinico-epidemiological Profile of Transfusion-dependent Thalassemia Patients in a Tertiary Care Children's Hospital in Nepal: An Observational Study.JNMA; journal of the Nepal Medical Association · 2025Observational
- The distribution and spectrum of thalassemia variants in GUIYANG region, southern China.Orphanet journal of rare diseases · 2025Article
- Endocrine complications in patients with β-thalassemia major receiving iron-chelation therapy.Therapeutic advances in endocrinology and metabolism · 2025Article
- The growth and development of children with β-thalassemia major one year after allogeneic hematopoietic stem cell transplantation.Translational pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundβ-Thalassemia major (BTM) is one of the most common hereditary anemias worldwide. Patients suffer from iron overload that results from repeated blood transfusion This in turn leads to multiple organ damage and endocrinopathies. This study aims to assess the prevalence of growth retardation, hypothyroidism, and diabetes mellitus in children and adolescents with BTM treated at Dubai Thalassemia Centre.
methodsA total of 105 children and adolescents were included in this retrospective observational study.
results39 children and 66 adolescents' data were analyzed. Females composed 51.3% (n = 20) of children and 53.0% (n = 35) of adolescents. Pretransfusion hemoglobin below 9 gm/dl was observed in 10.8% (n = 4) and 10.6% (n = 7) in children and adolescents, respectively. The mean age of menarche was 13.5 years. Among all study participants, 22.6% (n = 14) had normal height velocity whereas 37.1% (n = 23) had reduced height velocity in one year and 40.3% (n = 25) had reduced height velocity in two consecutive years. The proportion of children and adolescents showing reduced height velocity was significantly higher in females compared to the males (90.6% versus 63.3%, respectively, Chi-square = 6.597, p-value = 0.010). Although none of the study participants had diabetes mellitus, 26.1% (n = 12/46) had pre-diabetes. Elevated TSH was observed in 14.7% (n = 5) children and 8.1% (n = 5) adolescents while low FT4 was reported in one child and one adolescent.
conclusionOf all endocrinopathies seen among children and adolescents with BTM, growth delay remains the main concern for this group of patients. Effective treatment is key to further reducing endocrinopathies. Although the sample size is limited, we postulate that the low percentage of endocrinopathies among children with BTM treated at Dubai thalassemia center and the low level of pretransfusion anemia reflect the effective transfusion and chelation at the center.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.